Specialties

No added benefit of relatlimab in the adjuvant melanoma setting

Presented By

Dr Georgina Long, Melanoma Institute Australia

Trial

Phase 3, RELATIVITY-098

Conference

ASCO 2025

Type

News article

5 June 2025 13:16

Management of atopic dermatitis in children in 2025

Presented By

Dr Marlies de Graaf, University Medical Center Utrecht, the Netherlands)

Conference

DDD 2025

Type

Peer-reviewed article

5 June 2025 12:03

Crucial role of TFAP2a in skin health unravelled

Presented By

Dr Jos Smits, Radboud University Medical Center, the Netherlands

Conference

DDD 2025

Type

Peer-reviewed article

5 June 2025 11:38

Emerging intralesional therapies for BCC

Presented By

Dr Antonio Cozzio, Kantonsspital St Gallen, Switzerland

Conference

DDD 2025

Type

Peer-reviewed article

5 June 2025 11:30

Diagnosis and management of atypical melanocytic lesions

Presented By

Dr Willeke Blokx, University Medical Center Utrecht, the Netherlands

Conference

DDD 2025

Type

Peer-reviewed article

5 June 2025 11:16

Expanding treatment armamentarium for actinic keratosis and Bowen’s disease

Presented By

Dr Klara Mosterd, Maastricht University Medical Center, the Netherlands

Conference

DDD 2025

Type

Peer-reviewed article

5 June 2025 11:07

Active psoriatic arthritis: POETYK PsA-2 trial results

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, POETYK PsA-2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:31

Excellent long-term data for TYK2 inhibitor ESK-001 in psoriasis

Presented By

Dr Andrew Blauvelt, Blauvelt Consulting LLC, MD, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:54

ICONIC-LEAD in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, ICONIC-LEAD

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:49

A ‘TYK’ above placebo: ICP-488 in plaque psoriasis

Presented By

Dr Xiaoguang Zhang, Second Hospital of Hebei Medical University, China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:44

TYK2 inhibitor D-2570 safe and effective in psoriasis

Presented By

Dr Ling Zhang, InventisBio Co., China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:42

Flexing upadacitinib dose adjustment for AD and itch relief

Presented By

Dr Melinda Gooderham, SKiN Health, Canada

Trial

Phase 3, FLEX-UP

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:36

ROCKET ignites interest in rocatinlimab

Presented By

Prof. Emma Guttman, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, ROCKET-Horizon

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:33

Reduced biopsy rate and improved malignancy rate with high-end imaging tool

Presented By

Dr Jordan Phillipps, Washington University School of Medicine, MO, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:24

Cutaneous immune-related AEs may predict toxicities in ICI-treated patients

Presented By

Elle Kim, John Hopkins University, MD, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:19

Clinical patterns and outcomes in hypopigmented mycosis fungoides

Presented By

Dr Jong Bin Park, Kosin University, South Korea

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:10

New anti-IL-23p19 inscribes its name on the plaque

Presented By

Dr Furen Zhang, Shandong Academy of Medical Science, China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:20

Post-hoc analysis of 3 large trials maps sex differences in PsA

Presented By

Dr Laura Coates, University of Oxford, UK

Trial

Phase 3, DISCOVER-1, DISCOVER-2, COSMOS

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:36

Global recruitment associated with higher placebo responses in PsA trials

Presented By

Dr Andreas Kerschbaumer, Medical University of Vienna, Austria

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:32

ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease

Presented By

Dr Greg Challener, Massachusetts General Hospital, MA, USA

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:09

Registry participation can enhance quality of rheumatology care

Presented By

Dr Gabriela Schmajuk, University of California, San Francisco, CA, USA

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:07

Meet the Trialist: Prof. Philip J. Mease on the bimekizumab clinical trial program in psoriatic arthritis

Expert

Prof. Philip J. Mease, Swedish Medical Center/Providence-St. Joseph Health, Seattle, WA, USA

Trial

Phase 3, BE OPTIMAL, BE COMPLETE, BE VITAL

Conference

ACR 2024

23 December 2024 14:39

3-Year results highlight durable effects of IL-13 inhibitor in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

ADjoin

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:59

IL-22RA1 inhibition shows potential in atopic dermatitis

Presented By

Dr Christine Bangert, Medical University Vienna, Austria

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:56

Lifelong psychosocial burden linked to early-onset atopic dermatitis

Editor

George Washington University School of Medicine, USA

Trial

Scars of Life

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:53

Second-generation selective PDE4 inhibitor shows promise in AD

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA)

Trial

Phase 2, ADESOS

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:50

Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema

Presented By

Prof. Ana Giménez-Arnau, Autonomous University of Barcelona, Spain

Trial

Phase 3, DELTA FORCE

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:33

Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

DELTA; LIBERTY-AD-HAFT

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:30

Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis

Presented By

Prof. Adam Reich, University of Rzeszów, Poland

Trial

Phase 3, GEMINI-1; GEMINI-2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:04

A new era of care: Artificial intelligence in psoriasis

Presented By

Prof. Alexander Navarini, University Hospital of Basel, Switzerland

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:00

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

Advanced BCC: histological subtype and time to complete response may predict tumour recurrence

Presented By

Dr Maria Mannino, Catholic University of the Sacred Heart, Italy

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:02

Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma

Presented By

Dr Minke Lucas, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, NADINA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:00

New neoadjuvant combinations in stage III melanoma

Presented By

Dr Alexander Menzies, University of Sydney, Australia

Trial

Phase 1/2, KEYMAKER-U02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:58

Long-term benefit of nivolumab, ipilimumab, and pembrolizumab: 10-year survival data

Trial

Phase 3, KEYNOTE-006, CheckMate 067

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:53

Advanced therapies show promising results in PsA real-world study

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

PRO-SPIRIT

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

Small protein targeting IL-17A effective in PsA management

Presented By

Prof. Philip Mease, University of Washington; Swedish Medical Center, WA, USA

Trial

Phase 2

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:37

Low IL-18: a hidden culprit of long COVID in patients with autoimmune disease

Presented By

Dr Jeffrey Sparks, Brigham and Women's Hospital, MA, USA

Trial

RheumCARD

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:29

Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma

Presented By

Prof. Christian Blank, Antoni van Leeuwenhoek, the Netherlands

Trial

Phase 3, NADINA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:16

Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma

Presented By

Prof. Axel Hauschild, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PIVOTAL

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:13

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By

Prof. Caroline Robert, Gustave Roussy, France

Trial

Phase 3, ILLUMINATE-301

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:09

How close are we to personalised medicine in psoriatic arthritis?

Presented By

Prof. Ennio Lubrano, University of Molise, Ital

Conference

IFPA 2024

Type

News article

17 July 2024 14:38

Genetic and immunological advances in risk assessment and treatment of psoriatic diseases

Presented By

Prof. Wilson Liao, University of California San Francisco, USA

Conference

IFPA 2024

Type

News article

17 July 2024 14:32

Using advances in the genetics of psoriatic disease to better predict treatment response

Presented By

Prof. Carl Goodyear, University of Glasgow, Scotland

Conference

IFPA 2024

Type

News article

17 July 2024 14:28

Depression complicates the management of psoriatic disease

Presented By

Dr Wiebke Sondermann, University Hospital Essen, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:20

The unfavourable role of obesity in psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:13

Managing obesity and fibromyalgia in psoriatic disease

Presented By

Prof. Philip Mease, University of Washington, USA

Conference

IFPA 2024

Type

News article

Presented By

Dr Oseme Etomi, Guy's and St Thomas' Hospital, UK

Conference

IFPA 2024

Type

News article

17 July 2024 13:44

Towards prevention of psoriatic arthritis in patients with psoriasis

Presented By

Prof. Laura Coates, University of Oxford, UK

Conference

IFPA 2024

Type

News article

17 July 2024 13:39

Diagnosing generalised pustular psoriasis

Presented By

Dr Siew Eng Choon, Monash University Malaysia

Conference

IFPA 2024

Type

News article

17 July 2024 13:37

Itch and pain are major components of psoriatic disease and require management

Presented By

Prof. Adam Reich; Dr Anushka Irani

Conference

IFPA 2024

Type

News article

17 July 2024 12:07

Can diet help with the management of psoriasis?

Presented By

Prof. Wendy Hall, King's College London, UK

Trial

APPLE; METRED-P

Conference

IFPA 2024

Type

News article

17 July 2024 12:00

Biologics in psoriatic arthritis: where we are and where we are headed

Presented By

Dr Vinod Chandran

Conference

IFPA 2024

Type

News article

17 July 2024 11:55

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

Improving risk classification in cutaneous squamous cell carcinoma

Presented By

Dr Marlies Wakkee, Erasmus MC Rotterdam, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:54

Phase 2, STRIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:01

Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:41

Amlitelimab leads to a high response 28 weeks after treatment discontinuation

Presented By

Prof. Stephan Weidinger, Christian-Albrechts-University Kiel, Germany

Trial

Phase 2, STREAM-AD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:35

Delgocitinib cream: A promising treatment option for chronic hand eczema

Presented By

Prof. Melinda Gooderham, Queens University, Canada

Trial

Phase 3, DELTA 3

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:31

SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?

Presented By

Allison Holt, UMass Chan Medical School, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:06

Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT Trial

Expert

Dr Andrew Blauvelt

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

22 April 2024 12:12

Lifileucel induces a durable response in heavily pretreated mucosal melanoma

Presented By

Dr Evidio Domingo-Musibay, Masonic Cancer Center, USA

Trial

Phase 2, C-144-01

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:15

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ADvocate; ADvantage

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:13

IL-13 inhibitor shows potential in atopic dermatitis

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA

Trial

Phase 2, TREK-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:08

Encouraging results for amlitelimab in atopic dermatitis

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, STREAM-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:03

Dual IL-17 blockade yields efficacy on joints and skin

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, BE OPTIMAL; BE COMPLETE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:27

High-dose subcutaneous spesolimab prevents GPP flares up to week 48

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 2, Effisayil 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:23

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:57

Women with psoriasis face increased adverse effects with systemic therapy

Presented By

Dr Fabio Verardi, University Hospital Zurich, Switzerland

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:50

Improved AI tool shows high sensitivity rates in skin cancer detection

Presented By

Dr Kashini Andrew, University Hospitals Birmingham NHS Foundation Trust, UK

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:46

Dermoscopy training combined with AI significantly improves skin cancer detection

Presented By

Dr Christian Dorado Cortez, University Hospital of Saint-Etienne, France

Conference

EADV 2024

Type

Peer-reviewed article

28 November 2023 09:43

Analysing the Link Between Psoriasis and Chronic Kidney Disease

20 October 2023 12:20

Strategies for Early Psoriatic Arthritis Recognition in Psoriasis Patients: GRAPPA Survey Findings

Trial

Review study, GRAPPA

20 October 2023 12:15

Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients

Presented By

Dr Maria Rita Lo Monaco, Catholic University of the Sacred Heart, Italy

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 16:27

Response-directed treatment personalisation in stage III melanoma

Presented By

Dr Irene Reijers, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, OpACIN-neo, PRADO

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:30

Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate76K

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:27

Vascular inflammation may be characteristic of PsA

Presented By

Dr Nienke Kleinrensink, UMC Utrecht, the Netherlands

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:18

Obesity in PsA is increasingly affecting male patients

Presented By

Dr Marlene Stirnimann-Agustoni, University Hospital of Zürich, Switzerland

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:13

PsA patients: highest risk of developing NAFLD

Presented By

Mr Anthony Harrison, Leeds Teaching Hospitals NHS Trust, UK

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:09

Biologics in psoriasis: can they prevent joint involvement?

Presented By

Ms Kathleen Miao, Keck School of Medicine of USC, CA, USA

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:46

Switching to risankizumab successful in IL-17 inhibitor non-responders

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, aIMM study

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:56

Novel, selective TYK2 inhibitor shows promise for psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine of University of California, LA, USA

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:51

As-needed ruxolitinib shows successful long-term symptom control in AD

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, TRuE-AD1 and TRuE-AD2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:43

Dupilumab: a viable option for atopic hand and foot eczema

Presented By

Prof. Eric Simpson, Oregon Health & Science University, OR, USA

Trial

Phase 3, LIBERTY-AD-HAFT

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:33

Topical roflumilast beneficial in atopic dermatitis

Presented By

Prof. Lawrence Eichenfield, University of California San Diego, CA, USA

Trial

Phase 3, INTEGUMENT-1 and INTEGUMENT-2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:27

IL-22 receptor blocker reduces itch and skin lesions in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:17

We bring the Conference to the Physician